Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs MK 2206 (Primary)
- Indications Head and neck cancer; Nasopharyngeal cancer
- Focus Therapeutic Use
- 30 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned End Date changed from 1 Mar 2012 to 1 May 2014 as reported by ClinicalTrials.gov.
- 11 May 2011 New trial record